Stockscreener 앱 받기
15.05
1.48%
0.22
전일 마감가:
$14.83
열려 있는:
$14.82
하루 거래량:
307.56K
Relative Volume:
10.99
시가총액:
$812.46M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$14.50
$16.16
1주일 범위
$13.29
$16.16
52주 변동 폭
$13.29
$16.16
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Compare EIKN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
15.05 | 800.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eikon Therapeutics Inc 주식(EIKN)의 최신 뉴스
Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News
Covington, Davis Polk Lead Eikon's Upsized $381M IPO - Law360
Eikon Therapeutics Shares Fall in Nasdaq Debut - marketscreener.com
Eikon IPO grows to biggest for biotech since 2024, raising nearly $400 million before stock falls in debut - The Business Journals
Eikon Therapeutics Opens At $17.05, IPO Priced At $18 By Investing.com - Investing.com Canada
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics, Inc. Rings the Opening Bell - Nasdaq
IPO Tracker 2026: Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow - BioSpace
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO - 1470 & 100.3 WMBD
Eikon Therapeutics raises $381M in IPO - Axios
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings - BioPharma Dive
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering - ChartMill
Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow - Benzinga
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
Eikon Therapeutics IPO: Pipeline, Technology Platform, Key Collaborations & Investment Highlights for 2026 - Minichart
Eikon aims high for NASDAQ listing: Public Equity Report - biocentury.com
IPO Rating: Eikon Therapeutics, Inc. - Smartkarma
Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO - BioWorld MedTech
Market Chatter: Merck Expected to Take $30 Million Stake in Eikon Therapeutics' IPO - 富途牛牛
Merck (MRK) Invests in Eikon Therapeutics' IPO - GuruFocus
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - MSN
Merck veteran Perlmutter-led Eikon ?Therapeutics eyes $908 million valuation in IPO - marketscreener.com
Eikon Therapeutics targets $317M raise in IPO - Axios
Eikon Therapeutics Eyes $908M Valuation in U.S. IPO Under Roger Perlmutter's Leadership - StockInvest.us
Eikon Therapeutics vise à lever 318 millions de dollars lors de son introduction en bourse aux États-Unis - TradingView
Merck to Acquire $30M Stake in Eikon Therapeutics - intellectia.ai
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development (Pending:EIKN) - Seeking Alpha
Inside Biotech: Eikon Therapeutics joins IPO queue with late-stage oncology focus - Proactive financial news
IPOs, whale-sized fundings and an animal testing debate ahead of biotech's big JPM conference - The Business Journals
Eikon, a high-profile startup led by Merck vets, seeks an IPO - BioPharma Dive
Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers. - renaissancecapital.com
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors - Business Wire
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - Business Wire
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting - Business Wire
Bay Area biotech company cuts 55 jobs, blames Trump-era funding reductions - San Francisco Chronicle
Eikon blames US funding cuts for 15% staff reduction centered on research tools business - Fierce Biotech
Eikon Therapeutics just raised $351 million — now it's cutting jobs thanks to Trump rollbacks - The Business Journals
In Vivo’s 2025 Rising Leaders - Citeline News & Insights
Eikon Therapeutics describes new WRN inhibitors - BioWorld MedTech
Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D - Crunchbase News
Eikon Therapeutics Inc (EIKN) 재무 분석
Eikon Therapeutics Inc (EIKN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):